Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 2/2021

01-02-2021 | Breast Cancer | Review Article

Tumor microenvironment promotes breast cancer chemoresistance

Authors: Umar Mehraj, Abid Hamid Dar, Nissar A. Wani, Manzoor A. Mir

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2021

Login to get access

Abstract

Breast cancer is presently the most predominant tumor type and the second leading cause of tumor-related deaths among women. Although advancements in diagnosis and therapeutics have momentously improved, chemoresistance remains an important challenge. Tumors oppose chemotherapeutic agents through a variety of mechanisms, with studies revealing that the tumor microenvironment (TME) is central to this process. The components of TME including stromal cells, immune cells, and non-stromal factors on exposure to chemotherapy promote the acquisition of resistant phenotype. Consequently, limited targeting of tumor cells leads to tumor recurrence after chemotherapy. Here, in this article, we summarize how TME alters chemotherapy responses in breast cancer. Furthermore, the role of different stromal cells viz., CAFs, TAMs, MSCs, endothelial cells, and cancer stem cells (CSC) in breast cancer chemoresistance is discussed in greater detail.
Literature
1.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA J Clin 68(6):394–424
2.
Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA J Clin 69(1):7–34
3.
Perou CM, Sørlie T, Eisen MB, Van De Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752
4.
Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Van De Rijn M, Jeffrey SS (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci 98(19):10869–10874PubMed
5.
6.
Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y, Gong Z, Zhang S, Zhou J, Cao K (2017) Role of tumor microenvironment in tumorigenesis. J Cancer 8(5):761PubMedPubMedCentral
7.
Bahrami A, Hassanian SM, Khazaei M, Hasanzadeh M, Shahidsales S, Maftouh M, Ferns GA, Avan A (2018) The therapeutic potential of targeting tumor microenvironment in breast cancer: rational strategies and recent progress. J Cell Biochem 119(1):111–122PubMed
8.
Samadi N, Barazvan B, Rad JS (2016) Tumor microenvironment-mediated chemoresistance in breast cancer. Breast 30:92–100PubMed
9.
Cassetta L, Pollard JW (2018) Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discovery 17(12):887–904PubMed
10.
Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR (2019) Targeting tumor microenvironment for cancer therapy. Int J Mol Sci 20(4):840PubMedCentral
11.
Shee K, Yang W, Hinds JW, Hampsch RA, Varn FS, Traphagen NA, Patel K, Cheng C, Jenkins NP, Kettenbach AN (2018) Therapeutically targeting tumor microenvironment–mediated drug resistance in estrogen receptor–positive breast cancer. J Exp Med 215(3):895–910PubMedPubMedCentral
12.
Jung YY, Kim HM, Koo JS (2015) The role of cancer-associated fibroblasts in breast cancer pathobiology. Histol Histopathol 31(4):371–378PubMed
13.
Chaiwun B, Sukhamwang N, Trakultivakorn H, Saha B, Young L, Tsao-Wei D, Naritoku WY, Groshen S, Taylor CR, Imam SA (2011) GSTPi-positive tumour microenvironment-associated fibroblasts are significantly associated with GSTPi-negative cancer cells in paired cases of primary invasive breast cancer and axillary lymph node metastases. Br J Cancer 105(8):1224–1229PubMedPubMedCentral
14.
Kim HM, Jung WH, Koo JS (2015) Expression of cancer-associated fibroblast related proteins in metastatic breast cancer: an immunohistochemical analysis. J Trans Med 13(1):222
15.
Park SY, Kim HM, Koo JS (2015) Differential expression of cancer-associated fibroblast-related proteins according to molecular subtype and stromal histology in breast cancer. Breast Cancer Res Treat 149(3):727–741PubMed
16.
Brechbuhl HM, Finlay-Schultz J, Yamamoto TM, Gillen AE, Cittelly DM, Tan A-C, Sams SB, Pillai MM, Elias AD, Robinson WA (2017) Fibroblast subtypes regulate responsiveness of luminal breast cancer to estrogen. Clin Cancer Res 23(7):1710–1721PubMed
17.
Huelsken J, Hanahan D (2018) A subset of cancer-associated fibroblasts determines therapy resistance. Cell 172(4):643–644PubMed
18.
Ueno T, Utsumi J, Toi M (2015) Shimizu K (2015) Characteristic gene expression profiles of human fibroblasts and breast cancer cells in a newly developed bilateral coculture system. BioMed Res Internat 12:10–34
19.
Xing Y, Zhao S, Zhou BP, Mi J (2015) Metabolic reprogramming of the tumour microenvironment. FEBS J 282(20):3892–3898PubMed
20.
Ryan MC, Orr DJA, Horgan K (1993) Fibroblast stimulation of breast cancer cell growth in a serum-free system. Br J Cancer 67(6):1268–1273PubMedPubMedCentral
21.
Martinez-Outschoorn UE, Goldberg AF, Lin Z, Ko Y-H, Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell A, Sotgia F (2011) Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biol Ther 12(10):924–938PubMedPubMedCentral
22.
Mueller KL, Madden JM, Zoratti GL, Kuperwasser C, List K, Boerner JL (2012) Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met. Breast Cancer Res 14(4):1–11
23.
Takai K, Le A, Weaver VM, Werb Z (2016) Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Oncotarget 7(50):82889PubMedPubMedCentral
24.
Loeffler M, Krüger JA, Niethammer AG, Reisfeld RA (2006) Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Investig 116(7):1955–1962PubMed
25.
Pontiggia O, Sampayo R, Raffo D, Motter A, Xu R, Bissell MJ, de Kier Joffé EB, Simian M (2012) The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin. Breast Cancer Res Treat 133(2):459–471PubMed
26.
Sansone P, Berishaj M, Rajasekhar VK, Ceccarelli C, Chang Q, Strillacci A, Savini C, Shapiro L, Bowman RL, Mastroleo C (2017) Evolution of cancer stem-like cells in endocrine-resistant metastatic breast cancers is mediated by stromal microvesicles. Can Res 77(8):1927–1941
27.
Mao Y, Zhang Y, Qu Q, Zhao M, Lou Y, Liu J, Chen X, Wu J, Shen K (2015) Cancer-associated fibroblasts induce trastuzumab resistance in HER2 positive breast cancer cells. Mol BioSyst 11(4):1029–1040PubMed
28.
Su S, Chen J, Yao H, Liu J, Yu S, Lao L, Wang M, Luo M, Xing Y, Chen F (2018) CD10+ GPR77+ cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness. Cell 172(4):841–856PubMed
29.
Chan T-S, Hsu C-C, Pai VC, Liao W-Y, Huang S-S, Tan K-T, Yen C-J, Hsu S-C, Chen W-Y, Shan Y-S (2016) Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells. J Exp Med 213(13):2967–2988PubMedPubMedCentral
30.
Apicella M, Giannoni E, Fiore S, Ferrari KJ, Fernández-Pérez D, Isella C, Granchi C, Minutolo F, Sottile A, Comoglio PM (2018) Increased lactate secretion by cancer cells sustains non-cell-autonomous adaptive resistance to MET and EGFR targeted therapies. Cell Metab 28(6):848–865PubMed
31.
32.
Mir MA, Mehraj U (2019) Double-crosser of the immune system: macrophages in tumor progression and metastasis. Curr Immunol Rev 15(2):172–184
33.
34.
Li B, Severson E, Pignon J-C, Zhao H, Li T, Novak J, Jiang P, Shen H, Aster JC, Rodig S (2016) Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol 17(1):1–16
35.
Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS (2017) TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Can Res 77(21):e108–e110
36.
Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B, Liu XS (2020) TIMER2. 0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res 12:20–45
37.
Zhang Q-w, Liu L, Gong C-y, Shi H-s, Zeng Y-h, Wang X-z, Zhao Y-w, Wei Y-q (2012) Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS ONE 7(12):e50946PubMedPubMedCentral
38.
Liu H, Wang J, Liu Z, Wang L, Liu S, Zhang Q (2017) Jagged1 modulated tumor-associated macrophage differentiation predicts poor prognosis in patients with invasive micropapillary carcinoma of the breast. Medicine 96(16):10–23
39.
Tiainen S, Tumelius R, Rilla K, Hämäläinen K, Tammi M, Tammi R, Kosma VM, Oikari S, Auvinen P (2015) High numbers of macrophages, especially M2-like (CD 163-positive), correlate with hyaluronan accumulation and poor outcome in breast cancer. Histopathology 66(6):873–883PubMed
40.
Sousa S, Brion R, Lintunen M, Kronqvist P, Sandholm J, Mönkkönen J, Kellokumpu-Lehtinen P-L, Lauttia S, Tynninen O, Joensuu H (2015) Human breast cancer cells educate macrophages toward the M2 activation status. Breast Cancer Res 17(1):101PubMedPubMedCentral
41.
Mahmoud SMA, Lee AHS, Paish EC, Macmillan RD, Ellis IO, Green AR (2012) Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol 65(2):159–163PubMed
42.
Yuan Z-Y, Luo R-Z, Peng R-J, Wang S-S, Xue C (2014) High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis. OncoTargets Therapy 7:1475PubMed
43.
Gwak JM, Jang MH, Kim DI, Seo AN, Park SY (2015) Prognostic value of tumor-associated macrophages according to histologic locations and hormone receptor status in breast cancer. PLoS ONE 10(4):e0125728PubMedPubMedCentral
44.
Mohammed ZM, Going JJ, Edwards J, Elsberger B, Doughty JC, McMillan DC (2012) The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. Br J Cancer 107(5):864–873PubMedPubMedCentral
45.
Zhang W-j, Wang X-h, Gao S-t, Chen C, Xu X-y, Zhou Z-h, Wu G-z, Yu Q, Xu G, Yao Y-Z (2018) Tumor-associated macrophages correlate with phenomenon of epithelial-mesenchymal transition and contribute to poor prognosis in triple-negative breast cancer patients. J Surg Res 222:93–101PubMed
46.
Klingen TA, Chen Y, Aas H, Wik E, Akslen LA (2017) Tumor-associated macrophages are strongly related to vascular invasion, non-luminal subtypes, and interval breast cancer. Hum Pathol 69:72–80PubMed
47.
Ali HR, Chlon L, Pharoah PDP, Markowetz F, Caldas C (2016) Patterns of immune infiltration in breast cancer and their clinical implications: a gene-expression-based retrospective study. PLoS Med 13(12):e1002194PubMedPubMedCentral
48.
Mantovani A, Allavena P (2015) The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med 212(4):435–445PubMedPubMedCentral
49.
Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson K, Bell-McGuinn KM, Zabor EC, Brogi E, Joyce JA (2011) Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev 25(23):2465–2479PubMedPubMedCentral
50.
Paulus P, Stanley ER, Schäfer R, Abraham D, Aharinejad S (2006) Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. Can Res 66(8):4349–4356
51.
DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1(1):54–67PubMedPubMedCentral
52.
Olson OC, Kim H, Quail DF, Foley EA, Joyce JA (2017) Tumor-associated macrophages suppress the cytotoxic activity of antimitotic agents. Cell Rep 19(1):101–113PubMedPubMedCentral
53.
Yang C, He L, He P, Liu Y, Wang W, He Y, Du Y, Gao F (2015) Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway. Med Oncol 32(2):14
54.
Yan D, Wang H-W, Bowman RL, Joyce JA (2016) STAT3 and STAT6 signaling pathways synergize to promote cathepsin secretion from macrophages via IRE1α activation. Cell Rep 16(11):2914–2927PubMedPubMedCentral
55.
Houthuijzen JM, Daenen LGM, Roodhart JML, Oosterom I, Van Jaarsveld MTM, Govaert KM, Smith ME, Sadatmand SJ, Rosing H, Kruse F (2014) Lysophospholipids secreted by splenic macrophages induce chemotherapy resistance via interference with the DNA damage response. Nat Commun 5:5275PubMed
56.
Usman MW, Gao J, Zheng T, Rui C, Li T, Bian X, Cheng H, Liu P, Luo F (2018) Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-κB signaling. Cell Death Dis 9(8):1–12
57.
Ren G, Liu Y, Zhao X, Zhang J, Zheng B, Yuan ZR, Zhang L, Qu X, Tischfield JA, Shao C (2014) Tumor resident mesenchymal stromal cells endow naive stromal cells with tumor-promoting properties. Oncogene 33(30):4016–4020PubMed
58.
Patel SA, Meyer JR, Greco SJ, Corcoran KE, Bryan M, Rameshwar P (2010) Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-β. J Immunol 184(10):5885–5894PubMed
59.
Rafii A, Mirshahi P, Poupot M, Faussat A-M, Simon A, Ducros E, Mery E, Couderc B, Lis R, Capdet J (2008) Oncologic trogocytosis of an original stromal cells induces chemoresistance of ovarian tumours. PLoS ONE 3(12):e3894PubMedPubMedCentral
60.
61.
62.
Malfuson JV, Boutin L, Clay D, Thépenier C, Desterke C, Torossian F, Guerton B, Anginot A, de Revel T, Lataillade JJ, Le Bousse-Kerdilès MC (2014) SP/drug efflux functionality of hematopoietic progenitors is controlled by mesenchymal niche through VLA-4/CD44 axis. Leukemia 28(4):853–864. https://​doi.​org/​10.​1038/​leu.​2013.​256CrossRefPubMed
63.
64.
65.
66.
67.
68.
69.
70.
71.
Zhu Y, Sun Z, Han Q, Liao L, Wang J, Bian C, Li J, Yan X, Liu Y, Shao C (2009) Human mesenchymal stem cells inhibit cancer cell proliferation by secreting DKK-1. Leukemia 23(5):925–933PubMed
72.
73.
Clarke MR, Imhoff FM, Baird SK (2015) Mesenchymal stem cells inhibit breast cancer cell migration and invasion through secretion of tissue inhibitor of metalloproteinase-1 and-2. Mol Carcinog 54(10):1214–1219PubMed
74.
75.
76.
77.
78.
Biroccio A, Candiloro A, Mottolese M, Sapora O, Albini A, Zupi G, Del Bufalo D (2000) Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line. FASEB J Off Pub Federation Am Soc Exp Biol 14(5):652–660. https://​doi.​org/​10.​1096/​fasebj.​14.​5.​652CrossRef
79.
Michaelis M, Klassert D, Barth S, Suhan T, Breitling R, Mayer B, Hinsch N, Doerr HW, Cinatl J, Cinatl J Jr (2009) Chemoresistance acquisition induces a global shift of expression of aniogenesis-associated genes and increased pro-angogenic activity in neuroblastoma cells. Mole Cancer 8:80. https://​doi.​org/​10.​1186/​1476-4598-8-80CrossRef
80.
81.
82.
83.
84.
Insua-Rodríguez J, Oskarsson T (2016) The extracellular matrix in breast cancer. Adv Drug Deliv Rev 97:41–55PubMed
85.
Xing H, Weng D, Chen G, Tao W, Zhu T, Yang X, Meng L, Wang S, Lu Y, Ma D (2008) Activation of fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells. Cancer Lett 261(1):108–119PubMed
86.
87.
Meads MB, Gatenby RA, Dalton WS (2009) Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 9(9):665–674PubMed
88.
Zhu L-C, Gao J, Hu Z-H, Schwab CL, Zhuang H-Y, Tan M-Z, Yan L-M, Liu J-J, Zhang D-Y, Lin B (2015) Membranous expressions of Lewis y and CAM-DR-related markers are independent factors of chemotherapy resistance and poor prognosis in epithelial ovarian cancer. Am J Cancer Res 5(2):830PubMedPubMedCentral
89.
90.
91.
Insua-Rodríguez J, Pein M, Hongu T, Meier J, Descot A, Lowy CM, De Braekeleer E, Sinn HP, Spaich S, Sütterlin M, Schneeweiss A, Oskarsson T (2018) Stress signaling in breast cancer cells induces matrix components that promote chemoresistant metastasis. EMBO Mole Med 10(10):45. https://​doi.​org/​10.​15252/​emmm.​201809003CrossRef
92.
93.
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci 100(7):3983–3988PubMed
94.
Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, Klein C, Saini M, Bäuerle T, Wallwiener M, Holland-Letz T, Höfner T, Sprick M, Scharpff M, Marmé F, Sinn HP, Pantel K, Weichert W, Trumpp A (2013) Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 31(6):539–544. https://​doi.​org/​10.​1038/​nbt.​2576CrossRefPubMed
95.
Kise K, Kinugasa-Katayama Y, Takakura N (2016) Tumor microenvironment for cancer stem cells. Adv Drug Deliv Rev 99:197–205PubMed
96.
Sun Y, Fan X, Zhang Q, Shi X, Xu G, Zou C (2017) Cancer-associated fibroblasts secrete FGF-1 to promote ovarian proliferation, migration, and invasion through the activation of FGF-1/FGFR4 signaling. Tumor Biol 39(7):1010428317712592
97.
Zhao XL, Lin Y, Jiang J, Tang Z, Yang S, Lu L, Liang Y, Liu X, Tan J, Hu XG (2017) High-mobility group box 1 released by autophagic cancer-associated fibroblasts maintains the stemness of luminal breast cancer cells. J Pathol 243(3):376–389PubMed
98.
Waugh DJJ, Wilson C (2008) The interleukin-8 pathway in cancer. Clin Cancer Res 14(21):6735–6741PubMed
99.
100.
101.
Wang T, Fahrmann JF, Lee H, Li Y-J, Tripathi SC, Yue C, Zhang C, Lifshitz V, Song J, Yuan Y (2018) JAK/STAT3-regulated fatty acid β-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance. Cell Metab 27(1):136–150PubMed
102.
103.
104.
Bartucci M, Dattilo R, Moriconi C, Pagliuca A, Mottolese M, Federici G, Benedetto AD, Todaro M, Stassi G, Sperati F, Amabile MI, Pilozzi E, Patrizii M, Biffoni M, Maugeri-Saccà M, Piccolo S, De Maria R (2015) TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene 34(6):681–690. https://​doi.​org/​10.​1038/​onc.​2014.​5CrossRefPubMed
105.
106.
107.
Das S, Kundu M, Parekh A, Bharadwaj D, Mandal M (2019) Cancer stem cell induces chemoresistance in breast cancer via macrophage migration inhibitory factor mediated activation of AKT pathway. AACR 12:10–34
108.
Metadata
Title
Tumor microenvironment promotes breast cancer chemoresistance
Authors
Umar Mehraj
Abid Hamid Dar
Nissar A. Wani
Manzoor A. Mir
Publication date
01-02-2021
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 2/2021
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-020-04222-w

Other articles of this Issue 2/2021

Cancer Chemotherapy and Pharmacology 2/2021 Go to the issue

Original Article

Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer

Original Article

Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types

Original Article

PDK4 promotes tumorigenesis and cisplatin resistance in lung adenocarcinoma via transcriptional regulation of EPAS1

Original Article

Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients

Original Article

Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1–XPF-mediated DNA repair

Short Communication

Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma: a case report and literature review
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits